75 results on '"Mathijssen, Ron H.J."'
Search Results
2. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
3. Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib.
4. Staging laparoscopy in gastric cancer patients: From a Dutch nationwide Delphi consensus towards a standardized protocol
5. Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma
6. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide
7. Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
8. Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment
9. Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non–Small Lung Cancer
10. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer
11. Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients
12. Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases
13. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients
14. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
15. Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma
16. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
17. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
18. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
19. Intraperitoneal irinotecan combined with systemic chemotherapy for extensive peritoneal carcinomatosis of colorectal origin: The phase I and phase II INTERACT trials
20. Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer
21. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS
22. Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands
23. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
24. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients
25. Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
26. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer
27. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
28. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer
29. The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis
30. Adding metabolic agents to prostate cancer therapy: Every rose has its thorn
31. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
32. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
33. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy
34. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer
35. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
36. Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation
37. Cross-resistance and drug sequence in prostate cancer
38. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors
39. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
40. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
41. A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours
42. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer
43. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application
44. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
45. Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
46. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
47. An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells
48. Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma
49. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib
50. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981–5
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.